Consenso chileno sobre Abobotulinumtoxina A (Dysport®): indicaciones, técnicas

par Chaná-Cuevas,Pedro, Benavides C,Olga, González H,Pilar, Aguilera A,Carlos, Arigon B,Estrella, Benavides,Olga, Canals C,María Francisca, Cueto U,Germán, Ferrada-Eguiluz,Verónica, Figueroa O,Claudia, González,Pilar, Gutiérrez P,Tania, Icarte B,Carmen, Klapp S,Cecilia, Mascayano M,Marcela, Miranda M,Ana Luisa, Pizarro A,Gonzalo, Tapia N,John, Zúñiga G,María Elena
Publié 2013

AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

par Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman Bahroo, Stefan Wietek
Publié 2021

Muscle Selection and Dosing in a Phase 3, Pivotal Study of AbobotulinumtoxinA Injection in Upper Limb Muscles in Children With Cerebral Palsy

par Joyce Oleszek, Ann Tilton, Jorge Carranza del Rio, Nigar Dursun, Marcin Bonikowski, Edward Dabrowski, Simon Page, Benjamin Regnault, Catherine Thompson, Mauricio R. Delgado
Publié 2021

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity

par Santamato A
Publié 2016

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

par Kongsaengdao S, Maneeton N, Maneeton B
Publié 2018